… aim of this paper is to review the current state of the model-based approaches to predict
clinical pharmacokinetics and DDIs of drugs or NMEs that are substrates of hepatic transporters. …

… , might alter uptake kinetics of a given drug substrate. This transporter-mediated drug-drug
interaction might be the second reason for adverse drug reactions. Since several widely …

… publications on hepatic drug transporter DDIs using static models that tackle interactions
with individual transporters and in combination with other drug transporters and metabolising …

… The major hepatic transporters involved in hepatic drug elimination will be briefly reviewed
in this article, along with the most important substrates and drug–drug interactions described …

… transporter-mediated pharmacokinetics and drug interactions. Decision trees for determining
when clinical drug interaction … on in vitro evaluations of transporter substrates and inhibitors …

… investigating the effects of drug-drug interactions (DDIs) or … drugs have shown that changes
in the expression/activity of membrane transporters, in addition to such changes in drug-…

… drug-drug interactions attributable to inhibition or induction of intestinal export transporters
[P-… )], to inhibition of hepatic uptake transporters [organic anion transporting polypeptides (…

… Given the role of human OATP1B1/1B3 as bilirubin (glucuronide) uptake transporters,
drug-drug interactions at the basolateral entry site of hepatocytes may lead to a reduced clearance …

… Since tacrolimus and diltiazem are known to be substrates andWor inhibitor for MDR1WP-gp
and CYP3A, drug interaction due to hepatic andWor intestinal CYP3A inhibition andWor …

… DDI drug-drug interaction OATP organic anion transporting polypeptide MRP multidrug
resistance associated protein BCRP breast cancer resistance protein P-gp P-glycoprotein SNP …